Gates Foundation Invests $50M in Tessera’s In Vivo Gene-Editing Therapy for Sickle Cell Disease

GSK Acquires IDRx for $1 Billion to Advance Precision Therapy for GIST

Scipher Medicine and Roivant Partner to Advance Precision Medicine in Rheumatology

Roche Secures FDA Clearance for VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail to Enhance B-Cell Lymphoma Diagnosis

Illumina Launches Pilot Proteomics Program with UK Biobank and Industry Partners

NavDx Test Expands Availability for Enhanced Surveillance in HPV+ Anal Cancer Patients

QIAGEN Enhances QIAcuity Digital PCR with Expanded Multiplexing Capabilities

Boehringer Ingelheim Licenses Synaffix’s ADC Technology to Advance Cancer Therapies

AIG Hospitals to Launch ₹800 Crore Oncology Centre with South-East Asia’s First Dynamic ARC Proton Therapy

Qiagen Secures FDA Clearance for QIAstat-Dx Gastrointestinal Panel

Ovation.io Launches Groundbreaking GLP-1 Research Dataset to Advance Precision Medicine

Kotak Invests ₹940 Crore in Neuberg Diagnostics to Drive Expansion and IPO Preparation

NICE Recommends Olaparib for BRCA-Mutated Advanced Breast Cancer

SOPHiA GENETICS and Platomics Collaborate to Streamline IVDR Compliance for Clinical Labs

India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Home
/
update
/
details

Scipher Medicine and Roivant Partner to Advance Precision Medicine in Rheumatology

NextEdge Admin

14 Jan 2025

2 min 6 sec

Scipher Medicine and Roivant have announced a strategic partnership to advance rheumatology drug discovery by integrating Scipher’s real-world clinical and genomic data into Roivant’s R&D efforts. This collaboration will leverage insights from Scipher’s PrismRA® precision medicine diagnostic to enhance drug development. Financial details were not disclosed.

PrismRA® is a blood test that uses 19 genomic markers to identify rheumatoid arthritis (RA) patients unlikely to respond to TNFi therapy, the most widely used drug class. By incorporating data from PrismRA®, Roivant aims to refine its drug development pipeline and improve treatment strategies.

“This partnership unites precision medicine with real-world evidence to accelerate transformative therapies,” said Reg Seeto, Scipher’s CEO. “By combining Scipher’s unique data with Roivant’s expertise in drug development, we are advancing personalized medicine.”

Brett Venker, Roivant’s Head of Real-World Evidence, added, “Integrating Scipher’s dataset with longitudinal patient records allows us to uncover deeper insights into disease progression and treatment response, driving more informed decision-making.”

Scipher Medicine leverages AI, network biology, and proprietary data through its SPECTRA Rx and Dx platforms to optimize drug development. It owns the largest RA genomic data asset and a biobank linked to over 3 million rheumatology patient records.

PrismRA® enables physicians to make data-driven treatment decisions, improving patient outcomes and reducing ineffective drug use.